



## Supplementary Figure 1


A



B




C




## Supplementary Figure 2


**A**



**B**




**C**



D


PBMC




# Supplementary Figure 3

**A**


## TIM-3 ligands




## 2B4 ligand



## LAG-3 ligands



**B**




**C**

### LV NY-ESO-1 (hPGK) $\Delta$ LNGFR (mCMV)



### LV (hPGK) HLA-A2




### LV /luc (hPGK) GFP (mCMV)




**D**

### A2<sup>pos</sup> ESO-1<sup>pos</sup> MM1.s




### Wild-type MM1.s




## Supplementary Figure 4




**A**




**B**



## Supplementary Figure 5




## Supplementary Figure 6




# Supplementary Figure 7


**A**




**B**




**C**




**D**









**E**



**F**




## Supplementary Figure 8


**A****B****C****D****E**

## Supplementary Figure 9

A



B



C

